No insider bought or sold Tcr2 Therapeutics Inc. in the last 12 months

$0Bought, 12 mo

$0Sold, 12 mo

Follow TCRR

TCRR over the last year

Prices for TCRR aren't in yet.

TCRR after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

18 insider filings since 2019, newest first

TCRRSell

Mpm Asset Management LLC · 10% owner

$132K−2.0%May 24

TCRRSell

Ansbert Gadicke · Director and 10% owner

$132K−1.0%May 24

TCRRBuy

Kevin C Tang · 10% owner

$88K+1.0%May 15

TCRRBuy

Kevin C Tang · 10% owner

$164K+2.0%May 10

TCRRBuy

Kevin C Tang · 10% owner

$548K+7.0%May 5

TCRRSell

Garry E Menzel · President and CEO

$35K−5.0%Dec 13

TCRRSell

Garry E Menzel · President and CEO

$32K−3.0%Dec 7

TCRRSell

Mayur Ian Somaiya · CFO

$70K−58.0%Dec 16

TCRRSell

Mayur Ian Somaiya · CFO

$110K−71.0%Nov 19

TCRRSell

Robert Hofmeister · Chief Scientific Officer

$502K−34.0%Nov 13

TCRRSell

Robert Hofmeister · Chief Science Officer

$382K−34.0%Nov 2

TCRRSell

Neil W Gibson · Director

$525K−100.0%Mar 27

TCRRSell

Patrick Baeuerle · Director

$1.8M−25.0%Dec 26

TCRRSell